Skip to main content
. 2020 May 5;14(6):1152–1169. doi: 10.1002/1878-0261.12682

Fig. 1.

Fig. 1

Aspirin sensitizes osimertinib in osimertinib‐resistant NSCLC patients and osimertinib‐resistant cells. (A) The chest CT examination showed the size of the patient's tumor reduction followed with aspirin and osimertinib concurrent treatment. (B) Summary of the gene alterations in each parental and resistant cell lines detected by next‐generation sequencing. (C) Cell viability was analyzed by MTT assay in parental PC‐9GR, H1975 cells and their corresponding osimertinib‐ and rociletinib‐resistant cells. Mean ± SEM. (D) Representative images of showing the colony formation ability of resistant PC‐9GROR and H1975‐OR cells. Histogram showed the colony cell numbers in the indicated groups. The colony formation rates are shown as the mean ± SD from three independent experiments. *P < 0.05 compared with control; † P < 0.05 compared with aspirin treatment alone; ‡ P < 0.01 compared with osimertinib treatment alone. (E) Ki67 proliferation assay of resistant PC‐9GROR cells and H1975‐OR cells with various treatments. Histogram showed the incorporation cells in the indicated groups, respectively Scale bars: 100 μm. Data are from three independent assays and are shown as the mean ± SD. *P < 0.05 compared with control; † P < 0.05 compared with aspirin treatment alone; ‡ P < 0.01 compared with osimertinib treatment alone. DAPI, 4′,6‐diamidino‐2‐phenylindole; Asp, aspirin; Osi, osimertinib.